As a result of investments in National projects and research and development, VT Bio has innovative patents and pipelines at home and abroad. In addition, we recently confirmed the function of regulatory T cells that are very effective for Alzheimer's disease among degenerative brain diseases and completed pre-clinical trial, and clinical trials are underway.
In order to meet the needs of investors, we are actively developing hair loss functional shampoo and hair loss treatments by securing new materials that are effective in preventing hair loss.
Currently, natural dementia treatment and depression medications are under clinical trials, and there are acute bronchitis treatments (Technical name: treatment for chronic obstructive pulmonary disease) that has been licensed for clinical 3 phases. (Technology transfer completed, Hanlim pharmaceutical)
VT BIO has designated the immune-regulatory cell treatment, which is widely seen as a next-generation Bio-New drug, as its future research project and is focusing its research capabilities. Domestic and foreign pharmaceutical companies are competing to develop treatments using regulatory T cells. Recently, a new paradigm has been formed in the development of degenerative brain disease treatments, with the publication of a thesis suggesting that regulatory T cells are involved in inflammatory brain diseases such as dementia, Parkinson’s disease and amyotrophic lateral sclerosis as well as general immune disorders.
Starting with natural product, VT BIO is pushing to upgrade R&D by increasing its research capabilities with immune-regulatory cellular therapy.Likewise, through active commercialization, I promise to become a company that contributes to the quality of human life and welfare.
Please continue to give your generous encouragement and support.